NATALIE DURR: Open Payments
NPI 1528361490 · NASHVILLE, TN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,096 in 118 payments from 13 companies in 2025. Trend: 2023 $0 · 2024 $1,322 · 2025 $2,096
Food & beverage: $2,096
| Company | Payments | Amount |
|---|---|---|
| Alkermes, Inc. | 19 | $408 |
| Teva Pharmaceuticals USA, Inc. | 19 | $358 |
| Neurocrine BioSciences, Inc. | 15 | $251 |
| Supernus Pharmaceuticals, Inc. | 23 | $204 |
| E.R. Squibb & Sons, L.L.C. | 9 | $177 |
| Vanda Pharmaceuticals Inc. | 9 | $170 |
| Janssen Pharmaceuticals, Inc | 9 | $165 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 5 | $147 |
| Otsuka America Pharmaceutical, Inc. | 4 | $100 |
| ABBVIE INC. | 3 | $62 |
Products named: ARISTADA, INGREZZA, UZEDY, Qelbree, COBENFY, INVEGA SUSTENNA, CAPLYTA, AUSTEDO XR.
Industry payments across TN — which companies pay providers there.
